glucosamine 6-phosphate | 26014-11-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: glucosamine 6-phosphate
• 英文别名: D-Mannosamin-6-phosphat；2-amino-O⁶-phosphono-2-deoxy-D-mannose；2-Amino-O⁶-phosphono-2-desoxy-D-mannose；O⁶-Phosphono-D-mannosamin；[(2R,3S,4R,5S)-5-amino-2,3,4-trihydroxy-6-oxohexyl] dihydrogen phosphate
• CAS: 26014-11-9
• 化学式: C₆H₁₄NO₈P
• 分子量: 259.153
• InChiKey: AEJSSXDYDSUOOZ-KVTDHHQDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -7.1
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  171
• 氢给体数：
  6
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  fructose 6-phosphate 在 glucosamine-6-phosphate synthase from Bacillus subtilis mutant with S₅₉₆D/V₅₉₇G/S₃₄₇H/G₂₉₉Q 作用下， 生成 glucosamine 6-phosphate
  参考文献：
  名称：

  10.1021/acschembio.4c00144

  摘要：

  DOI：

  10.1021/acschembio.4c00144

文献信息

• [EN] MONOSACCHARIDE PHOSPHORAMIDATE PRODRUGS<br/>[FR] PROMÉDICAMENTS À BASE DE PHOSPHORAMIDATE DE MONOSACCHARIDE
  申请人：CERECOR INC

  公开号：WO2019118486A1

  公开（公告）日：2019-06-20

  The present disclosure provides monosaccharide phosphoramidate prodrugs of monosaccharide monophosphates. The present disclosure further provides methods of treating diseases of conditions such as congenital disorders of glycosylation comprising administering the monosaccharide phosphoramidate prodrugs of the present disclosure to a patient in need thereof.

  本公开提供了单糖磷酰胺酯前药，用于单糖单磷酸。本公开还提供了治疗糖基化先天性疾病等疾病或症状的方法，包括向需要的患者施用本公开的单糖磷酰胺酯前药。
• GLMS RIBOSWITCHES, STRUCTURE-BASED COMPOUND DESIGN WITH GLMS RIBOSWITCHES, AND METHODS AND COMPOSITIONS FOR USE OF AND WITH GLMS RIBOSWITCHES
  申请人：Breaker Ronald R.

  公开号：US20100324123A1

  公开（公告）日：2010-12-23

  The glmS riboswitch is a target for antibiotics and other small molecule therapies. Compounds can be used to stimulate, active, inhibit and/or inactivate the glmS riboswitch. The atomic structures of the glmS riboswitch can be used to design new compounds to stimulate, active, inhibit and/or inactivate riboswitches.

  glmS核酸开关是抗生素和其他小分子治疗的靶点。化合物可以用于刺激、激活、抑制和/或失活glmS核酸开关。glmS核酸开关的原子结构可用于设计新的化合物，以刺激、激活、抑制和/或失活核酸开关。
• Enzyme immunoassay
  申请人：Bayer Corporation

  公开号：EP0292171A2

  公开（公告）日：1988-11-23

  An analyte in a test sample is analysed by forming a mixture of: a) the sample containing the analyte under assay; b) an enzyme capable of mediating a process which yields a detectable signal; c) a conjugate comprising the same analyte as is under assay, covalently bonded to a reaction intermediate or reaction intermediate analog for the enzyme, the reaction intermediate or analog moiety of said conjugate being capable of transferring an activating group to the active site of the enzyme whereby the process mediated by the enzyme is initiated; d) a specific binding partner of the analyte, said specific binding partner being capable of binding to said conjugate, whereby said reaction intermediate or analog moiety is restricted from transferring said activating group to the enzyme; e) the elements of the process mediated by the enzyme; and measuring the detectable signal produced by the process mediated by the enzyme and therefrom determining the amount of analyte in the sample. A test composition comprises the enzyme, the conjugate, the binding partner and the signal generating process reagents.

  在分析检测样品中的分析物时，需要将以下物质混合： a) 含有被分析物的样品； b) 能够介导产生可检测信号的过程的酶； c) 一种共轭物，包含与被分析物相同的分析物，与酶的反应中间体或反应中间体类似物共价键合，所述共轭物的反应中间体或类似物能够将活化基团转移到酶的活性位点，从而启动由酶介导的过程； d) 分析物的特异性结合伙伴，所述特异性结合伙伴能够与所述共轭物结合，从而限制所述反应中间体或类似物将所述活化基团转移到酶； e) 由酶介导的过程要素； 测量由酶介导的过程产生的可检测信号，并由此确定样品中分析物的含量。 测试组合物包括酶、共轭物、结合伴侣和信号产生过程试剂。
• Analysis of saccharide vaccines without interference
  申请人：Novartis Vaccines and Diagnostics S.r.l.

  公开号：EP2290366A1

  公开（公告）日：2011-03-02

  The invention provides two batches of a vaccine, wherein: (a) each of the batches of vaccine comprises: a conjugate of a capsular saccharide from serogroup C of Neisseria meningitidis and one or both of: (i) a conjugate of a capsular saccharide from serogroup W135 of Neisseria meningitidis; and/or (ii) a conjugate of a capsular saccharide from serogroup Y of Neisseria meningitidis; (b) the concentration of conjugated serogroup C saccharide in the first batch is C1; (c) the concentration of conjugated serogroup C saccharide in the second batch is C2; if applicable, (d) the concentration of conjugated serogroup W135 saccharide in the first batch is W1; if applicable, (e) the concentration of conjugated serogroup W135 saccharide in the second batch is W2; if applicable, (f) the concentration of conjugated serogroup Y saccharide in the first batch is Y1; if applicable, (g) the concentration of conjugated serogroup Y saccharide in the second batch is Y2; and wherein (h) the ratios C1/C2, W1/W2 and Y1/Y2 are each between 0.90 and 1.10.

  本发明提供了两批疫苗，其中(a) 每批疫苗包括：脑膜炎奈瑟氏菌 C 血清群的荚膜糖和以下一种或两种荚膜糖的共轭物：(i) 来自脑膜炎奈瑟菌 W135 血清群的荚膜糖苷的共轭物；和/或 (ii) 来自脑膜炎奈瑟菌 Y 血清群的荚膜糖苷的共轭物； (b) 第一批疫苗中共轭血清 C 族糖苷的浓度为 C1；(c) 第二批中的共轭血清群 C 糖的浓度为 C2； (d) 第一批中的共轭血清群 W135 糖的浓度为 W1；如果适用，(e)第二批中共轭血清 W135 族糖的浓度为 W2； 如果适用，(f)第一批中共轭血清 Y 族糖的浓度为 Y1； 如果适用，(g)第二批中共轭血清 Y 族糖的浓度为 Y2；以及 其中(h)C1/C2、W1/W2 和 Y1/Y2 的比率分别介于 0.90 和 1.10 之间。
• Analysis of mannosamine-containing capsular saccharides
  申请人：Novartis AG

  公开号：EP2402751A1

  公开（公告）日：2012-01-04

  Analysis of compositions that include saccharides having mannosamine residues, such as the capsular saccharide of N.meningitidis serogroup A, is facilitated by a method comprising the steps of: (i) hydrolysing polysaccharide in the sample, to give a hydrolysate; (ii) subjecting the hydrolysate to liquid chromatography; and (iii) detecting any mannosamine-6-phosphate separated in step (ii).

  一种方法有助于分析包括具有甘露胺残基的糖类的成分，如脑膜炎双球菌 A 血清群的荚膜糖，该方法包括以下步骤：(i) 水解样品中的多糖，得到水解物；(ii) 将水解物进行液相色谱分析；(iii) 检测步骤 (ii) 中分离出的甘露胺-6-磷酸。